Study to Determine the Maximum Tolerated Dose of Liposome-Encapsulated C-RAF Antisense Oligodeoxynucleotide (LErafAON) in Patients With Advanced Solid Tumors
Latest Information Update: 06 Nov 2021
At a glance
- Drugs LErafAON (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 17 Sep 2014 New trial record